Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion

Core Viewpoint - Tevogen Bio Holdings Inc. is set to receive $1 million in grant funding to enhance its artificial intelligence-driven drug discovery program, Tevogen.AI, as part of a larger grant agreement potentially totaling $10 million [1][2][6]. Funding Details - The new $1 million funding is part of a previously announced grant agreement with KRHP LLC, which includes an initial $2 million received in January 2025 and may allow for an additional $8 million [2][6]. - The total potential funding of $10 million is categorized as non-dilutive, meaning it will not dilute existing shareholders' equity [2][6]. Strategic Focus - The funding will be directed towards improving Tevogen.AI's capabilities, specifically in target discovery, development timelines, and treatment accessibility for large patient populations [2][3]. - The company emphasizes its commitment to operational efficiency and strategic fund deployment to maximize shareholder value and patient impact [3]. Leadership Statement - Dr. Ryan Saadi, Chairman and CEO of Tevogen, highlighted the grant as an endorsement of Tevogen.AI's potential to accelerate drug development, reduce costs, and enhance access to precision cell therapies [3].